RA
CRSP icon

Rise Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Rise Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60
Closed -$2.82K – 1139
2024
Q3 		$2.82K Hold
60
– – ﹤0.01% 1110
2024
Q2 		$3.24K Hold
60
– – ﹤0.01% 1096
2024
Q1 		$4.09K Hold
60
– – ﹤0.01% 1099
2023
Q4 		$3.76K Hold
60
– – ﹤0.01% 406
2023
Q3 		$2.72K Hold
60
– – ﹤0.01% 435
2023
Q2 		$3.37K Hold
60
– – ﹤0.01% 451
2023
Q1 		$2.71K Hold
60
– – ﹤0.01% 532
2022
Q4 		$2.43K Hold
60
– – ﹤0.01% 536
2022
Q3 		$4K Hold
60
– – ﹤0.01% 459
2022
Q2 		$4K Hold
60
– – ﹤0.01% 467
2022
Q1 		$4K Hold
60
– – ﹤0.01% 444
2021
Q4 		$4.55K Buy
+60
New +$5.24K ﹤0.01% 415

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rise Advisors's CRSP Position: Q4 2024 in Review

Rise Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 60 shares — an estimated $2.82K sold.

Rise Advisors first reported a position in CRSP in Q4 2021 and held it in 12 quarters. The position peaked at $4.55K in Q4 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Rise Advisors reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Rise Advisors sold 60 CRISPR Therapeutics shares in Q4 2024, an estimated $2.82K.
  • Rise Advisors first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 12 quarters.
  • Rise Advisors's CRISPR Therapeutics position peaked at $4.55K in Q4 2021.
  • 404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Rise Advisors's 13F filing for Q4 2024, filed 7 Jan 2025.